| 1. |
Fluoxetine now first line SSRI for paediatric MDD |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1419,
2004,
Page 2-2
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 2. |
EU Parliament approves pharma legislative package |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1419,
2004,
Page 3-3
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 3. |
Developing therapies for protein misfolding diseases |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1419,
2004,
Page 4-4
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 4. |
Benefit of newer antipsychotics not clear cut |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1419,
2004,
Page 5-5
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 5. |
Patients with migraine have only a"slight increased use of antidepressants"compared with the population without migraine, |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1419,
2004,
Page 6-6
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 6. |
Ximelagatran simplifies stroke prevention for patients with AF |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1419,
2004,
Page 7-8
RM Poole,
Preview
|
|
摘要:
The first oral direct thrombin inhibitor, ximelagatran [Exanta] offers advantages over warfarin in the prevention of stroke and systemic embolic events in high-risk patients with atrial fibrillation (AF), according to results from the SPORTIF V study presented at the 76th Annual Scientific Sessions of the American Heart Association [Orlando, US; November 2003].*This study, which involved almost 4000 patients, showed that ximelagatran was as effective as warfarin in reducing the incidences of fatal or disabling stroke and haemorrhagic stroke, but was associated with a lower combined incidence of major and minor bleeding.
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 7. |
A multicentre, phase III clinical trial of secretin*for the treatment of paediatric autism has failed to meet its dual primary endpoints |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1419,
2004,
Page 8-8
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 8. |
IFN alfacon-1 may be valuable in the treatment of SARS |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1419,
2004,
Page 9-9
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 9. |
Artemisinin combinations ACTive against malaria |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1419,
2004,
Page 10-10
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 10. |
Rofecoxib: an alternative to naproxen in juvenile RA? |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1419,
2004,
Page 11-12
C Bankhead,,
Preview
|
|
摘要:
Selective inhibitors of cyclo-oxygenase (COX)-2 have demonstrated efficacy at least comparable to that of NSAIDs in the treatment of rheumatoid arthritis and acute and chronic pain. Data from research studies and experience in clinical practice have shown that COX-2 inhibitors have a favourable safety profile compared with NSAIDs, particularly with respect to adverse gastrointestinal effects. However, the efficacy and safety of selective COX-2 inhibitors in patients with juvenile rheumatoid arthritis (JRA) has remained undetermined. Results from the first clinical study to evaluate a COX-2 inhibitor in JRA, presented at the 67th Annual Scientific Meeting of the American College of Rheumatology (ACR) [Orlando, US; October 2003], indicate that rofecoxib [Vioxx] has efficacy comparable to that of the NSAID naproxen. The overall safety and tolerability profiles of the two agents were comparable, although a trend towards fewer gastrointestinal adverse events was observed in patients treated with rofecoxib.
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
首页
Volume &NA; issue 1419